Stock S1RP34 SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Sarepta Therapeutics, Inc. Sao Paulo

Equities

S1RP34

BRS1RPBDR005

Delayed Sao Paulo
Other stock markets
 01:31:29 2024-07-12 pm EDT 		5-day change 1st Jan Change
40.97 BRL -1.13% Intraday chart for Sarepta Therapeutics, Inc. -1.32% +78.44%
Jun. 26 Monetary policy is getting even more confusing Our Logo
Jun. 26 Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Health Care Stocks Boosted By Duchenne MS Drug -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Gain in Late Afternoon
MT
S&P, Nasdaq edge down as Nvidia declines for second day
RE
Top Midday Gainers
MT
Sector Update: Health Care Stocks Edge Up in Afternoon Trading
MT
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says
MT
S&P 500, Nasdaq lower as semiconductor shares weigh
RE
Sarepta surges as investors cheer expanded use of gene therapy
RE
Sector Update: Health Care Stocks Steady Premarket Friday
MT
Sector Update: Health Care
MT
Wavering Tech Rally Pushes Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Friday
MT
Top Premarket Gainers
MT
Sarepta surges as investors cheer expanded use of gene therapy
RE
Futures Down Pre-Bell as Traders Wait for Market Direction Cues; Asia, Europe Fall
MT
Wall Street futures edge lower ahead of business survey data
RE
Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
MT
Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket
MT
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours
MT
US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump
RE
US FDA allows expanded use of Sarepta's Duchenne gene therapy
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. S1RP34 Stock
  5. News Sarepta Therapeutics, Inc.
  6. Highlights